Literature DB >> 36212248

WEIGHT LOSS EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN PATIENTS WITH OBESITY WITHOUT DIABETES: A SYSTEMATIC REVIEW.

K G Pratama1,2, K Tandarto2, A Hengky2.   

Abstract

Context: Obesity is a chronic disorder with excessive accumulation and hypertrophy of adipose cells. Selective sodium-glucose cotransporter-2 (SGLT2) Inhibitor has shown an effect of weight loss in several studies. However, weight loss in patients with obesity without diabetes remains unclear. Objective: This systematic review aims to address the weight loss effects of SGLT 2 inhibitors in obese subjects without diabetes.
Methods: We incorporated search engines from Pubmed, EBSCO host, and Proquest. The inclusion criteria for this research were full-text, written in English, written in Bahasa Indonesia, reported the effect of SGLT 2 inhibitors for weight loss in obese patients, the design of the studies, outcomes, and the results of the study. We created a data extraction table to gather the required data for the review. The exclusion criteria for this study were incomplete outcomes, not full-text studies, case reports, literature review, and irrelevant studies.
Results: A total of 451 studies were identified from research database. There are 7 studies eligible to be included in this review. Weight loss effects of SGLT2 Inhibitors were observed in all the studies included in this review.
Conclusion: SGLT2 inhibitor is an effective weight loss therapy in patients with obesity without diabetes. ©2022 Acta Endocrinologica (Buc).

Entities:  

Keywords:  Obesity; SGLT2 Inhibitors; Weight Loss

Year:  2022        PMID： 36212248      PMCID： PMC9512389          DOI： 10.4183/aeb.2022.216

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN： 1841-0987            Impact factor:   1.104


  20 in total

Review 1.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

Review 2.  Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review.

Authors:  Habib Yaribeygi; Thozhukat Sathyapalan; Mina Maleki; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Life Sci       Date:  2019-11-22       Impact factor: 5.037

3.  Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.

Authors:  Priscilla Hollander; Harold E Bays; Julio Rosenstock; Mary Ellen Frustaci; Albert Fung; Frank Vercruysse; Ngozi Erondu
Journal:  Diabetes Care       Date:  2017-03-13       Impact factor: 19.112

4.  Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

Authors:  J Bolinder; Ö Ljunggren; L Johansson; J Wilding; A M Langkilde; C D Sjöström; J Sugg; S Parikh
Journal:  Diabetes Obes Metab       Date:  2013-08-29       Impact factor: 6.577

5.  Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

Authors:  Ele Ferrannini; Simona Baldi; Silvia Frascerra; Brenno Astiarraga; Tim Heise; Roberto Bizzotto; Andrea Mari; Thomas R Pieber; Elza Muscelli
Journal:  Diabetes       Date:  2016-02-09       Impact factor: 9.461

6.  Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes.

Authors:  Alejandra M Ramírez-Rodríguez; Manuel González-Ortiz; Esperanza Martínez-Abundis
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-08-27       Impact factor: 2.949

7.  Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.

Authors:  Antonella Napolitano; Sam Miller; Peter R Murgatroyd; Elizabeth Hussey; Robert L Dobbins; Edward T Bullmore; Derek J R Nunez
Journal:  J Clin Transl Endocrinol       Date:  2013-12-11

8.  Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.

Authors:  Hanrui Zheng; Min Liu; Sheyu Li; Qingyang Shi; Shengzhao Zhang; Yiling Zhou; Na Su
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-16       Impact factor: 5.555

9.  Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.

Authors:  Ralph A DeFronzo; Marcus Hompesch; Sreeneeranj Kasichayanula; Xiaoni Liu; Ying Hong; Marc Pfister; Linda A Morrow; Bruce R Leslie; David W Boulton; Agatha Ching; Frank P LaCreta; Steven C Griffen
Journal:  Diabetes Care       Date:  2013-06-04       Impact factor: 19.112

10.  Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.

Authors:  Harold E Bays; Richard Weinstein; Gordon Law; William Canovatchel
Journal:  Obesity (Silver Spring)       Date:  2013-12-09       Impact factor: 5.002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.